BioSenic S.A. patent granted in Canada for broader protection of its ATO therapeutic platform; Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration; Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. The second is in oncology, where ATO has already demonstrated exceptional results for patients, including complete remission in acute promyelocytic leukaemia. These patents will support BioSenic's plans for international clinical trials in pathologies with unmet medical needs, toward the company's long-term goal of seeking market access approvals for its various formulations, optimizing the original properties of arsenic salts - alone or in combination.

The expected availability of an oral formulation that combines arsenic and copper puts BioSenic in a unique position to build on clinical successes in its fields of applications. As a result, BioSenic will be able to continue clinical development with proprietary original formulations containing arsenic and new active ingredients such as metal ions, increasing the potency of its products, and minimizing secondary side effects. The Canadian patent, corresponding to Application 3,138,472, was granted to Medsenic, a subsidiary of BioSenic.